|
|
LP-GMP |
|
Vaxjo ID |
380 |
|
Vaccine Adjuvant Name |
LP-GMP |
|
Alternative Names |
LP-GMP refers to the combination of LP1569 (a TLR2 agonist) and c-di-GMP (a STING agonist). |
|
Adjuvant VO ID |
VO_0005648
|
|
Description |
LP-GMP is a novel adjuvant combination designed to enhance immune responses by promoting Th1 and Th17 cells, leading to sustained protective immunity against Bordetella pertussis. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
A novel adjuvant combination (called LP-GMP), comprising c-di-GMP, an intracellular receptor stimulator of interferon genes (STING) agonist, and LP1569, a TLR2 agonist from B. |
|
Structure |
It is a combination of two components: LP1569 (a TLR2 agonist) and c-di-GMP (a STING agonist). |
|
Preparation |
LP-GMP is prepared by combining LP1569 and c-di-GMP, which synergistically enhance immune responses when used as an adjuvant with vaccines. |
|
Function |
Type: synthetic vaccine adjuvant. Target Receptor: protein MB21D1 (cGAS) | Toll-like receptor 2 (TLR2). Induces Th1-biased immune profile. induces production of IFN-尾, IL-12 and IL-23, and maturation of dendritic cells. Parenteral immunization of mice with an experimental aP vaccine formulated with LP-GMP promoted Th1 and Th17 responses and conferred protection against lung infection with B. pertussis. Intranasal immunization with the same aP vaccine-induced potent B. pertussis-specific Th17 responses and IL-17-secreting respiratory tissue-resident memory (TRM) CD4 T cells, and conferred a high level of protection against nasal colonization as well as lung infection, which was sustained for at least 10 months. Furthermore, long-term protection against nasal colonization with B. pertussis correlated with the number of IL-17-secreting TRM cells in nasal tissue. Our study has identified an approach for inducing IL-17-secreting TRM cells that sustain sterilizing immunity against nasal colonization of mice with B. pertussis, and could form the basis of a third generation pertussis vaccine for humans. |
|
Safety |
The article indicates that LP-GMP does not induce inflammatory cytokines in the olfactory bulb or brain, suggesting a favorable safety profile compared to other adjuvants. |
| References |
Allen et al., 2018: Allen AC, Wilk MM, Misiak A, Borkner L, Murphy D, Mills KHG. Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting T(RM) cells. Mucosal immunology. 2018; 11(6); 1763-1776. [PubMed: 30127384].
|
|
